Skip to content

Released Nov 13, 2026, after the close

10-Q filed Nov 13, 2026, 44 days after period end · 0001683168-26-008697

Q3 2026 · 10-Q
Revenue—
Net Income-$3.42MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.14N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$3,439,087N/M
Operating Cash Flowderived-$2,950,806N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Net Income-$3.42M-$5.41M-$5.97M-$6.34M
EPS Diluted-$0.14-$0.25-$0.55-$4.31

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR